RE: What difference weill CE make?1 Dec 2021 18:25
Accepted PCR tech.
Novel point of Care SCV2 test (7.5-17 mins turnaround)
'Substantial market'
£8M cash
Sales network and team with lots of interest already generated as per RNS.
£28M Mcap
David Budd, CEO of genedrive plc, said: "We are at an exciting phase for the Company with both the AIHL and CoV-POC products about to enter their commercial stages. Our balance sheet is strengthened following the recent equity raise and we are well placed to drive shareholder value going forwards."
Enough said.